Here's Why Corbus Pharmaceuticals Holdings Inc. Jumped Today
In response to upbeat results released from a phase 2 clinical trial, shares of Corbus Pharmaceuticals (NASDAQ: CRBP), a clinical-stage biotech focused on inflammatory and fibrotic diseases, jumped by 14% as of 11 a.m. EDT on Thursday.
Corbus announced topline results from a 16-week phase 2 study evaluating its lead compound anabasum as a hopeful treatment for dermatomyositis, a rare disease that affects about 70,000 Americans each year.
The study showed that patients who used anabasum show an improvement on the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) activity score of 9.3 points. That was a statistically significant gain when compared to the 3.7 point improvement observed in the placebo group.
Source: Fool.com
Corbus Pharmaceuticals Holding Inc. Stock
€44.40
1.440%
With 2 Buy predictions and 1 Sell predictions the community is currently undecided on Corbus Pharmaceuticals Holding Inc..
With a target price of 50 € there is a slightly positive potential of 12.61% for Corbus Pharmaceuticals Holding Inc. compared to the current price of 44.4 €.
